Genetic characterization of the murine type I Interferon locus
小鼠 I 型干扰素基因座的遗传特征
基本信息
- 批准号:8623890
- 负责人:
- 金额:$ 23.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-12-10 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:Adoptive TransferAntiviral AgentsAttentionAutoimmune DiseasesAutoimmunityBiological ProcessCD8-Positive T-LymphocytesCD8B1 geneChromosomes, Human, Pair 4DataDevelopmentElementsEpitheliumEvaluationFamilyFamily memberGenesGeneticHematopoietic stem cellsHomeostasisHumanIFNAR1 geneImmuneImmune responseImmunologic MonitoringIndividualInterferon ActivationInterferon Type IInterferon Type IIInterferonsKnockout MiceMalignant NeoplasmsMediatingMicrobeMusNatural Killer CellsPatternPlayPsoriasisRNA Sequence AnalysisRegulationReportingRoleSignal TransductionSyndromeSystemic Lupus ErythematosusT-LymphocyteTherapeuticTissuesViraladaptive immunityatopyautocrinebasecytokinedesignembryonic stem cellgenetic pedigreein vivoinsightinterestmembermicrobiomepathogenpressurepublic health relevancereceptorresponsetooltumortype I interferon receptorvector
项目摘要
In addition to their potent antiviral activity, type I Interferons (IFN-Is) are increasingly
recognized for the important role they play in regulating immune homeostasis, both basally and
during an immune challenge. Intriguingly, recent studies suggest the microbiome may play an
important role in directing basal activity, which notably includes regulation of hematopoietic stem
cells (HSCs), and several lineages they give rise to (e.g., DCs, NK cells & CD8 T-cells). IFN-Is
also play an important role during the innate response to viral and bacterial pathogens,
whereupon they direct the transition to an effective adaptive response. Consistent with this,
IFN-Is have recently been found to play a prominent role in several autoimmune diseases (e.g.,
systemic lupus erythematosis [SLE], Sj¿gren's syndrome, psoriasis & atopy) and in tumor
immunosurveillance. Reflecting these important discoveries have been renewed interest in
developing more specific IFN-I based therapeutics to treat autoimmunity, cancer and to
manipulate HSCs.
Remarkably, in humans the IFN-I family consists of 17 well-curated members, at least half of
which are highly conserved, raising the intriguing question of whether they serve distinct
biological functions. Unfortunately, the size of the IFN-I locus has precluded the development of
effective tools to explore this important question. To this end we have developed targeting
vectors that will enable us to either delete the entire IFN-I locus (i.e., IFN-Ilocus-/- mice) or to
generate mice in which only the IFN-¿ gene is retained (i.e., IFN-¿only mice). The latter mouse
will help evaluate the prevailing notion that IFN-¿ directs the basal IFN-I response.
Two aims are proposed to complete the development and analysis of these mice. These
data will be vital for subsequent studies in which these two lines will be exploited to explore the
role that individual IFN-Is play in vivo.
Aim I. Exploit IFN-Ilocus-/- and IFN-¿only mice to explore the role IFN-¿ plays in regulating
basal immune homeostasis. This will include evaluation of HSC and NK cell compartments.
Aim II. Exploit IFN-Ilocus-/- and IFN-¿ mice to explore the role IFN-¿ plays in directing both
only
robust innate and adaptive responses to specific microbes.
除了其有效的抗病毒活性外,I 型干扰素 (IFN-Is) 越来越多地被
公认它们在调节基础和免疫稳态方面发挥的重要作用
在免疫挑战期间。有趣的是,最近的研究表明微生物组可能发挥着重要作用
在指导基础活动中发挥重要作用,特别是造血干的调节
细胞 (HSC) 及其产生的几种谱系(例如 DC、NK 细胞和 CD8 T 细胞)。干扰素Is
在对病毒和细菌病原体的先天反应中也发挥着重要作用,
随后,他们指导过渡到有效的适应性反应。与此相一致的是,
最近发现 IFN-Is 在多种自身免疫性疾病(例如,
系统性红斑狼疮 [SLE]、干燥综合征、牛皮癣和特应性)和肿瘤
免疫监视。反映这些重要发现的人们重新燃起了对
开发更具体的基于 IFN-I 的疗法来治疗自身免疫、癌症和
操纵 HSC。
值得注意的是,在人类中,IFN-I 家族由 17 个精心挑选的成员组成,其中至少一半是
它们是高度保守的,提出了一个有趣的问题:它们是否具有独特的作用
生物学功能。不幸的是,IFN-I基因座的大小阻碍了
探索这个重要问题的有效工具。为此,我们制定了目标
载体将使我们能够删除整个 IFN-I 基因座(即 IFN-Ilocus-/- 小鼠)或
产生仅保留 IFN-¿ 基因的小鼠(即,仅 IFN-¿ 小鼠)。后者的鼠标
将有助于评估 IFN-¿ 指导基础 IFN-I 反应的普遍观点。
提出了两个目标来完成这些小鼠的开发和分析。这些
数据对于后续研究至关重要,其中将利用这两条线来探索
单个 IFN-Is 在体内发挥的作用。
目标 I. 利用 IFN-Ilocus-/- 和 IFN-only 小鼠来探索 IFN-¿ 在调节中的作用
基础免疫稳态。这将包括 HSC 和 NK 细胞区室的评估。
目标二。利用 IFN-Ilocus-/- 和 IFN-¿ 小鼠探索 IFN-¿ 在指导两者中的作用
仅有的
对特定微生物的强大的先天和适应性反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTIAN W SCHINDLER其他文献
CHRISTIAN W SCHINDLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTIAN W SCHINDLER', 18)}}的其他基金
Genetic characterization of the murine type I Interferon locus
小鼠 I 型干扰素基因座的遗传特征
- 批准号:
8780594 - 财政年份:2013
- 资助金额:
$ 23.7万 - 项目类别:
Probing the Innate Response to 3', 5'-cyclic Diguanylate (c-diGMP)
探索对 3, 5-环二鸟苷酸 (c-diGMP) 的先天反应
- 批准号:
8274633 - 财政年份:2011
- 资助金额:
$ 23.7万 - 项目类别:
Probing the Innate Response to 3', 5'-cyclic Diguanylate (c-diGMP)
探索对 3, 5-环二鸟苷酸 (c-diGMP) 的先天反应
- 批准号:
8176709 - 财政年份:2011
- 资助金额:
$ 23.7万 - 项目类别:
IFN-Is at the interface of Innate and Adapative Immunity
IFN-Is 位于先天免疫和适应性免疫的界面
- 批准号:
7916939 - 财政年份:2009
- 资助金额:
$ 23.7万 - 项目类别:
Characterization of the Innate Immune Response to Crystalline Silica
对结晶二氧化硅的先天免疫反应的表征
- 批准号:
7512740 - 财政年份:2009
- 资助金额:
$ 23.7万 - 项目类别:
Characterization of the Innate Immune Response to Crystalline Silica
对结晶二氧化硅的先天免疫反应的表征
- 批准号:
7846828 - 财政年份:2009
- 资助金额:
$ 23.7万 - 项目类别:
FLUORESCENCE-ACTIVATED CELL SORTER: STEM CELLS: ADULT HUMAN, ADULT MOUSE
荧光激活细胞分选仪:干细胞:成年人类、成年小鼠
- 批准号:
6973147 - 财政年份:2004
- 资助金额:
$ 23.7万 - 项目类别:
IFN-Is at the interface of Innate and Adapative Immunity
IFN-Is 位于先天免疫和适应性免疫的界面
- 批准号:
7391145 - 财政年份:2004
- 资助金额:
$ 23.7万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 23.7万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 23.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 23.7万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:














{{item.name}}会员




